% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Courade:283060,
      author       = {Courade, Jean-Philippe and Zetterberg, Henrik and
                      Höglinger, Günter U and Dewachter, Ilse},
      title        = {{T}he evolving landscape of {A}lzheimer's disease therapy:
                      {F}rom {A}β to tau.},
      journal      = {Cell},
      volume       = {188},
      number       = {26},
      issn         = {0092-8674},
      address      = {[Cambridge, Mass.]},
      publisher    = {Cell Press},
      reportid     = {DZNE-2025-01467},
      pages        = {7337 - 7354},
      year         = {2025},
      abstract     = {A marked evolution in Alzheimer's disease (AD) therapy
                      research is ongoing. In this perspective, we highlight
                      emerging outcomes of tau-targeting approaches with
                      disease-modifying potential evidenced by PET-based slowing
                      of tau accumulation and early signs of cognitive benefit. We
                      outline how decades of iterative amyloid β (Aβ)-trial
                      refinement leading to the recent successes of approved
                      anti-Aβ therapies have set the stage for accelerated
                      optimization of next-generation trials. We summarize key
                      learnings from first-generation tau immunotherapies and how
                      these paved the way for early achievements in tau trials,
                      while many challenges remain. Finally, we discuss the
                      back-translation of clinical outcomes into fundamental
                      insights on human tau pathobiology, and we outline
                      challenges and future directions for AD therapy development
                      including combination therapy and targets beyond Aβ/tau.
                      Together, this provides a framework for next-generation AD
                      and tau-therapy development toward increasingly efficient
                      disease-halting interventions.},
      subtyp        = {Review Article},
      keywords     = {Alzheimer Disease: therapy / Alzheimer Disease: metabolism
                      / Alzheimer Disease: drug therapy / Alzheimer Disease:
                      pathology / Humans / tau Proteins: metabolism / tau
                      Proteins: antagonists $\&$ inhibitors / Amyloid
                      beta-Peptides: metabolism / Amyloid beta-Peptides:
                      antagonists $\&$ inhibitors / Immunotherapy: methods /
                      Animals / Clinical Trials as Topic / A(I)TN (Other) / ASO
                      (Other) / AT(X)N (Other) / ATN (Other) / Abeta therapy
                      (Other) / Alzheimer's disease (Other) / PET imaging (Other)
                      / amyloid (Other) / anti-sense oligonucleotides (Other) /
                      clinical trial (Other) / immunization (Other) / inflammation
                      (Other) / neurodegeneration (Other) / next-generation
                      therapies (Other) / tau (Other) / tau therapy (Other) /
                      tauopathies (Other) / therapy development (Other) / trial
                      (Other) / tau Proteins (NLM Chemicals) / Amyloid
                      beta-Peptides (NLM Chemicals)},
      cin          = {Clinical Research (Munich)},
      ddc          = {610},
      cid          = {I:(DE-2719)1111015},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41448139},
      doi          = {10.1016/j.cell.2025.11.033},
      url          = {https://pub.dzne.de/record/283060},
}